---
title: Differentiating TYK2 inhibitors with real-world evidence in psoriasis
description: Discover how real-world evidence guided a leading pharmaceutical firm in launching a TYK2 inhibitor for psoriasis, revealing key market insights and targeting strategies for success.
image: https://info.healthverity.com/hubfs/differentiating-tyk2-inhibitors-featured.png
---

- [Contact](https://healthverity.com/contact/)
- [Sign In](https://marketplace.healthverity.com/)

[![HealthVerity](https://info.healthverity.com/hs-fs/hubfs/raw_assets/public/Healthverity_May2023/images/healthverity-2023-logo2x.png?width=300&height=58&name=healthverity-2023-logo2x.png "HealthVerity")](https://healthverity.com/)

- How We Help 
    - New Products 
          - [HealthVerity TAXONOMY](https://healthverity.com/taxonomy-portal/)
          - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/)
    - HealthVerity Marketplace 
          - [Overview](https://healthverity.com/marketplace/)
          - [HealthVerity Marketplace](https://healthverity.com/marketplace/healthverity-marketplace/)
          - [Data Ecosystem](https://healthverity.com/marketplace/data-ecosystem/)
          - [Media Measurement](https://healthverity.com/media-measurement/)
          - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/)
    - HealthVerity Mastersets 
          - [Overview](https://healthverity.com/mastersets/)
          - [Maternal Outcomes Masterset](https://healthverity.com/mastersets/mom/)
          - [Chronic Kidney Disease Masterset](https://healthverity.com/mastersets/chronic-kidney-disease/)
          - [Mortality Masterset](https://healthverity.com/mastersets/mortality/)
          - [COVID-19 Masterset](https://healthverity.com/mastersets/covid-19/)
    - HealthVerity FLOW 
          - [Overview](https://healthverity.com/flow/)
          - [HealthVerity FLOW for Clinical Trials](https://healthverity.com/flow/clinical-trials/)
          - [HealthVerity FLOW for Commercial](https://healthverity.com/flow/commercial/)
          - [HealthVerity FLOW for Registries](https://healthverity.com/flow/registries/)
          - [Identity Manager](https://healthverity.com/identity-manager/)
          - [Governance Manager](https://healthverity.com/governance-manager/)
          - [Smart Contracts Manager](https://healthverity.com/smart-contracts-manager/)
          - [Audience Manager](https://healthverity.com/audience-manager/)
- Who We Serve 
    - [Life Sciences](https://healthverity.com/life-sciences/)
    - [Government](https://healthverity.com/government/)
    - [Insurance](https://healthverity.com/insurance/)
    - [Channel Partners](https://healthverity.com/channel-partners/)
    - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
- Resources 
    - [HealthVerity Blog](https://blog.healthverity.com/)
    - [News & Events](https://healthverity.com/resources/news-and-events/)
    - [Resource Library](https://healthverity.com/resources/resource-library/)
    - [Publications](https://healthverity.com/resources/publications/)
    - [The IPGE Approach](https://healthverity.com/ipge-approach/)
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)

![differentiating-tyk2-inhibitors-landing](https://info.healthverity.com/hs-fs/hubfs/differentiating-tyk2-inhibitors-landing.png?width=813&height=301&name=differentiating-tyk2-inhibitors-landing.png)

###### CASE STUDY

# Differentiating TYK2 inhibitors with real-world evidence in psoriasis

For a competitive drug launch, the difference between share gained and share lost often comes down to how well the brand team understands the market before day one. This case study shows how a leading pharmaceutical manufacturer used real-world evidence to sharpen launch strategy for an oral TYK2 inhibitor in psoriasis, uncovering targeting opportunities that fragmented data would have missed.

### What you'll learn:

- Why the growth pathway apremilast used to expand the psoriasis market points to a similar opportunity for oral TYK2 inhibitors, and how to identify the topical-to-systemic patients most ready to advance
- How linking patients to prescribers across a longitudinal cohort revealed NPs and PAs as high-value targets in community dermatology, reshaping the field force targeting plan
- How real-world insights on free drug program dynamics, treatment discontinuation and prescriber behavior can inform differentiated positioning before launch, when the decisions that define share are still on the table

© 2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/)

![](https://px.ads.linkedin.com/collect/?pid=4361946&fmt=gif)